Free Trial

GT Biopharma Q1 2023 Earnings Report

GT Biopharma logo
$2.31 -0.08 (-3.35%)
As of 01/21/2025 04:00 PM Eastern

GT Biopharma EPS Results

Actual EPS
-$2.40
Consensus EPS
-$4.80
Beat/Miss
Beat by +$2.40
One Year Ago EPS
N/A

GT Biopharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GT Biopharma Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

GT Biopharma Earnings Headlines

GT Biopharma initiated with a Buy at Roth MKM
Trump currency shock imminent
Trump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launched a $1.9 trillion move against the Fed. What comes next could have dramatic consequences.
GT Biopharma Reports Third Quarter 2024 Financial Results
See More GT Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GT Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GT Biopharma and other key companies, straight to your email.

About GT Biopharma

GT Biopharma (NASDAQ:GTBP), a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

View GT Biopharma Profile

More Earnings Resources from MarketBeat